Clinical trials
Locally Advanced Breast Carcinoma clinical trials
Below are recruiting locally advanced breast carcinoma clinical trials, each written for real people, not researchers. We’re tracking 351 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04215731RecruitingPhase 3
Chemo plus targeted drug before surgery for high-risk rectal cancer
This trial tests giving chemotherapy (mFOLFOXIRI) plus bevacizumab before surgery for rectal cancer that has higher-risk features. It aims to shrink or control the cancer early to improve outcomes after treatment.
Guangzhou, GuangdongAges 18–70 - NCT04383119RecruitingPhase 2
Study for advanced leiomyosarcoma after prior chemo
This Phase 2 trial studies how well gemcitabine or trabectedin works for people with leiomyosarcoma that cannot be fully removed or has spread. It’s for tumors that have grown or worsened despite prior standard chemotherapy.
Bologna, BOAges 18 years+ - NCT04495088RecruitingPhase 3
Before vs after chemotherapy for locally advanced rectal cancer
This Phase 3 study compares giving chemotherapy before rectal surgery versus giving it after surgery, using a tailored plan based on your risk. The goal is to see which timing helps more people with locally advanced rectal cancer stay cancer-free and live longer.
MannheimAges 18 years+ - NCT05201430RecruitingPhase 3
FOLFOXIRI vs CapeOX before surgery for locally advanced rectal cancer
This trial compares two chemotherapy plans given before rectal cancer surgery to see which helps more people and works better for disease control. If you have locally advanced rectal cancer and have not had treatment yet, this study may be an option.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05262491RecruitingPhase 1
Early drug study for advanced GI or solid cancers that failed treatment
This Phase 1 trial tests BL-B01D1, a new cancer medicine, in people with advanced or metastatic gastrointestinal or other solid tumors that did not respond to standard treatment (or cannot use standard treatment). It also looks at whether a tumor marker called TROP2 may help predict who benefits.
Beijing, Beijing MunicipalityAges 18–75 - NCT05388773RecruitingPhase 2
Surgery then lower-dose radiation for p16+ throat cancer
This Phase 2 study tests whether removing the tumor through the mouth, followed by a reduced course of radiation, can control HPV-related (p16+) oropharynx throat cancer. It may help reduce treatment intensity after surgery, while still aiming to keep the cancer from coming back.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05442060RecruitingPhase 2
Test medicine add-on to erlotinib for EGFR lung cancer
This Phase 2 trial tests whether adding OBI-833/OBI-821 to the standard targeted pill erlotinib works better for some people with EGFR-mutated lung cancer. It may help shrink tumors that already started responding to erlotinib.
Taipei, Beitou DistrictAges 20 years+ - NCT05468242RecruitingPhase 2
Tislelizumab after lung cancer chemotherapy and radiation
This Phase 2 study tests tislelizumab (an immune medicine) given after chemotherapy and radiation for stage III non-small cell lung cancer that has not been treated before. It may help improve how well the cancer responds and how long patients can stay in remission, with or without an added medication called bevacizumab.
GuangzhouAges 18–75 - NCT06204991RecruitingPhase 1
T-cell therapy for advanced melanoma
This trial tests a new treatment called ADP-TILIL7 for people with advanced melanoma. It uses your own immune cells (T-cells) that are taken from a tumor, multiplied in a lab, and then given back to you to fight the cancer. The goal is to see if this treatment is safe and works better than standard options.
HerlevAges 18–75 - NCT06358677RecruitingPhase 2
Tretinoin cream to prevent skin rash from EGFR drugs
This study tests whether a topical tretinoin cream can prevent the skin rash often caused by anti-EGFR drugs like panitumumab or cetuximab. It is for people with advanced solid tumors who are about to start one of these treatments.
Salt Lake City, UtahAges 18 years+ - NCT06524167Recruiting
Radiation therapy after surgery for advanced thyroid cancer
This study looks at whether adding radiation therapy after surgery can help people with thyroid cancer that is at high risk of coming back. It includes different types of thyroid cancer, like differentiated and medullary types.
ShanghaiAges 14–80 - NCT06558981RecruitingPhase 3
Radiation therapy after thyroid surgery for high-risk cancer
This trial is testing whether giving radiation therapy after thyroid surgery can help destroy any leftover cancer cells in people with high-risk differentiated thyroid cancer. It is for those who had surgery but some cancer was still left behind.
ShanghaiAges 14–80 - NCT06567015RecruitingPhase 1/Phase 2
STX-241 for advanced EGFR-mutant lung cancer after TKI failure
This trial tests an experimental drug called STX-241 for people with a specific type of advanced lung cancer (NSCLC) that has an EGFR mutation (exon 19 deletion or L858R) and has stopped responding to a third-generation EGFR inhibitor (like osimertinib). The drug aims to target a new mutation, C797X, that sometimes appears after osimertinib stops working.
Nashville, TennesseeAges 18 years+ - NCT06576921RecruitingPhase 2
Study of serplulimab with chemo before surgery for stomach cancer
This trial tests if adding serplulimab to standard chemotherapy before surgery can help shrink locally advanced stomach or gastroesophageal junction cancer. It aims to improve treatment outcomes for patients who are candidates for surgery.
Shijiazhuang, Heibei ProvinceAges 18–75 - NCT06770270RecruitingPhase 2
Immunotherapy with radiation and chemo before rectal cancer surgery
This trial tests adding an immunotherapy drug (pucotenlimab) to standard radiation and chemotherapy before surgery for locally advanced rectal cancer. The goal is to see if this combination can shrink the tumor more effectively and improve outcomes.
Hangzhou, ZhejiangAges 18–75 - NCT06793917RecruitingPhase 3
Immunotherapy plus chemo vs. chemo alone for advanced stomach cancer
This trial compares two types of chemotherapy with or without an immunotherapy drug (tislelizumab) for advanced stomach or gastroesophageal junction cancer. It aims to see which combination works better and has fewer side effects.
Fuzhou, FujianAges 18–70 - NCT06826079RecruitingPhase 2/Phase 3
Sorbitol plus chemo and immunotherapy for advanced gastric cancer
This trial tests adding sorbitol to standard chemotherapy and an immunotherapy drug (tirellizumab) for people with locally advanced stomach cancer. The goal is to see if this combination is safe and helps shrink tumors before surgery.
Wuhan, HubeiAges 18–70 - NCT06895447RecruitingPhase 2
Robot-assisted stomach cancer surgery after chemo or radiation
This trial tests whether using a robotic arm to remove stomach cancer is safe and effective for patients who have already received chemotherapy or radiation. If you have stage III stomach cancer and are healthy enough for surgery, this approach may offer a more precise operation.
Nanjing, JiangsuAges 18–80 - NCT07005102RecruitingPhase 2/Phase 3
Telisotuzumab adizutecan and osimertinib for EGFR-positive lung cancer
This trial tests a new drug combination (telisotuzumab adizutecan plus osimertinib) as a first treatment for adults with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination is safe and works better than standard care.
Chandler, ArizonaAges 18 years+ - NCT07042685RecruitingPhase 2
5-FU and Fruquintinib for advanced colorectal cancer
This trial tests a combination of two drugs (5-FU and fruquintinib) in people with advanced colorectal cancer that cannot be removed by surgery or has spread. It is for those who have not had chemotherapy before.
Houston, TexasAges 18 years+ - NCT07103395RecruitingPhase 2
Study of chemo, radiation, and dual immunotherapy for stage 3 lung cancer
This trial tests combining chemotherapy, radiation therapy, and two immune-boosting drugs (iparomlimab and tuvonralimab) as a first treatment for locally advanced non-small cell lung cancer that cannot be surgically removed. It aims to see if this combination improves outcomes compared to standard care.
Guangzhou, GuangdongAges 18–75 - NCT07108127RecruitingPhase 2
Targeted drugs plus chemo for HER2-positive rectal cancer
This trial tests whether a combination of two targeted drugs (trastuzumab and pertuzumab biosimilars) plus chemotherapy can shrink advanced HER2-positive rectal cancer before surgery. It aims to improve response and potentially reduce the need for more aggressive treatments.
BeijingAges 18 years+ - NCT07183150Recruiting
Lymph node removal range for advanced stomach cancer
This study is looking at how far surgeons should remove lymph nodes during surgery for advanced stomach cancer. It may help doctors decide the best way to remove cancer while reducing side effects.
Tianjin, Tianjin MunicipalityAges 18–80 - NCT07222631RecruitingPhase 1/Phase 2
Study of SB-4826 for advanced solid tumors or lymphomas
This trial tests a new drug, SB-4826, for people with advanced solid tumors or certain types of lymphoma that have not responded to standard treatments. The goal is to see if the drug is safe and effective, either alone or with another drug called rituximab.
La Jolla, CaliforniaAges 18 years+
Hear when a new Locally Advanced Breast Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced breast carcinoma?
- Yes. Clin2 currently lists 351 recruiting locally advanced breast carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced breast carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced breast carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced Triple-Negative Breast Carcinoma
- Locally Advanced Breast Cancer
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Rectal Carcinoma
- Locally Advanced Head and Neck Squamous Cell Carcinoma
- Locally Advanced Nasopharyngeal Carcinoma
- Locally Advanced Cervical Carcinoma
- Locally Advanced Esophageal Squamous Cell Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.